Hapray (002399.SZ): H1710 completes the first subject enrollment and first dose administration in Phase I clinical trials.

The Zhitong Financial APP news, Hai Pu Rui (002399.SZ) announced that the company's independently developed innovative candidate drug injection H1710 (referred to as "H1710") Phase I clinical trial has completed the first subject's enrollment and first dosing.